See the DrugPatentWatch profile for qulipta
What is Qulipta?
Qulipta (atogepant) is a prescription medication used to prevent migraine headaches. It belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists.
When Will Qulipta Go Generic?
The exact date when a generic version of Qulipta becomes available depends on patent expirations and potential market challenges. Information on patent status can be found at DrugPatentWatch.com [1].
How Does Qulipta Work?
Qulipta works by blocking the action of CGRP, a molecule that plays a role in migraine pain. By inhibiting CGRP, the drug helps to reduce the frequency of migraine attacks.
Who Makes Qulipta?
Qulipta is manufactured by AbbVie Inc. [2].
What Are the Risks of Taking Qulipta?
Common side effects of Qulipta can include upper respiratory infection, nausea, and diarrhea. More serious side effects are possible but less common [3]. Patients should discuss potential risks with their healthcare provider.
How Does Qulipta Compare to Other Migraine Preventatives?
Qulipta is a CGRP receptor antagonist, distinguishing it from older preventive migraine medications that include beta-blockers, antidepressants, and anti-seizure drugs. These different classes of drugs work through various mechanisms to prevent migraines.
What is the Cost of Qulipta?
The cost of Qulipta can vary depending on insurance coverage and pharmacy. Patients may have access to savings programs offered by the manufacturer.
Sources
1. DrugPatentWatch.com
2. AbbVie Inc.
3. Qulipta prescribing information